2021-01-31-accounts - Diabetes Care Trust (Abcd) Limited

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

		Page
Reference and Administrative Details
Report of the Trustees	2	to	4
Independent Examiner's Report
Statement of Financial Activities
Balance Sheet	7	to	8
Notes to the Financial Statements	9	to	16
Detailed Statement of Financial Activities	17	to	18

for the Ye	ar Ended		1 Janua	2021
								2021	2020
						Unrestricted	Restricted	Total	Total
						fund	funds	funds	funds
					Notes	6	f	6	F
INCOME	AND ENDOWMENTS			FROM
Donations	and legacies					4,521		4,521	122,389
Charitable	activities
Charitable	activities						227,819	227,819	226,642
Investment	income				3	4,341		4,341	4,816
Total						8,862	227,819	236,681	353,847
EXPENDITURE ON
Charitable	activities
Charitable	activities					9,842	148,536	158,378	226,027
Net gains	on investments					17,267		17,267	20,486
NET INCOME						16,287	79,283	95,570	148,306
Transfers	between		funds		10	(42,782)	42,782
Net movement in funds						(26,495)	122,065	95,570	148,306
RECONCILIATION		OF FUNDS
Total funds brought			forward			1,082,281	395,626	1,477,907	1,329,601
TOTAL FUNDS CARRIED FORWARD						1,055,786	517,691	1,573,477	1,477,907

Balance Sheet 3~1J 2021
				2021	2020
		Unrestricted	Restricted	Total	Total
		fund	funds	funds	funds
	Notes	5	6	F	6
FIXEDASSETS
Investments	7	234,123		234,123	212,770
CURRENT ASSETS
Debtors	8	421,607	241,304	662,911	504,419
Cash at bank		402,484	421,954	824,438	837,727
		824,091	663,258	1,487,349	1,342,146
CREDITORS
Amounts falling due within one year	9	(2,428)	(145,567)	(147,995)	(77,009)
NET CURRENT ASSETS		821,663	517,691	1,339,354	1,265,137
TOTAL ASSETS LESSCURRENT
LIABILITIES		1,055,786	517,691	1,573,477	1,477,907
NET ASSETS		1,055,786	517,691	1,573,477	1,477,907
FUNDS	10
Unrestricted funds				1,055,786	1,082,281
Restricted funds				517,691	395,626
TOTAL FUNDS				1,573,477	1,477,907

INVESTMENT	INVESTMENT	INCOME
			2021		2020
			E		6
Dividend	income		4,329		4,791
Deposit	account	interest		12	25
			4,	341	4,816

No employee received remuneration amounting to more than	No employee received remuneration amounting to more than	No employee received remuneration amounting to more than	860,000 in eit	her year.
COMPARATIVES FOR THE STATEMENT OF FINANCIAL			ACTIVITIES
			Unrestricted	Restricted	Total
			fund	funds	funds
			8	F	8
INCOME AND ENDOWMENTS		FROM
Donations	and legacies		122,389		122,389
Charitable	activities
Charitable	activities			226,642	226,642
Investment	income		4,816		4,816
Total			127,205	226,642	353,847
EXPENDITURE ON
Charitable	activities
Charitable	activities		15,578	210,449	226,027
Net gains	on investments		20,486		20,486
NET INCOME			132,113	16,193	148,306

for t	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021	he Year Ended 31 Janua 2021
	COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES											-continued
										Unrestricted		Restricted	Total
											fund	funds	funds
											E	F	6
	Transfers between	funds									(41,293)	41,293
	Net movement in funds										90,820	57,486	148,306
	RECONCILIATION OF FUNDS
	Total funds brought	forward									991,461	338,140	1,329,601
	TOTAL FUNDS CARRIED FORWARD									1,082,281		395,626	1,477,907
7.	FIXEDASSET INVESTMENTS
							Shares		in
							gl'oup				Listed	Other
						undertakings F				investments F		investments 6	Totals f
	MARKET VALUE
	At 1 February 2020 Additions										191,128 8,493	21,641	212,770 8,493
	Disposals Revaluations										(4,407) 18,565	(1,298)	(4,407) 17,267
	At 31 January 2021									213,779		20,343	234,123
	NET BOOK VALUE
	At 31 January 2021									213,779		20,343	234,123
	At 31 January 2020										191,128	21,641	212,770
	There were no investment		assets		outside	the	UK.
	The company owns	100%of the			issued share		capital		of	ABCD (Diabetes		Care) Limited, a company
	incorporated and registered			in	England	and	Wales.			The	aggregate	capital and	reserves of t
	company at 31 January to 31 January 2021 was		2021 827,	were f25,149(2020: 325 (2020; fNil). The					8-2,176).The profit loss of the company			of the company for the ye for the year to 31 Januar
	2021 was Nil (2020:	E2,326).
	DEBTORS: AMOUNTS		FALLING DUE WITHIN					ONE YEAR
												2021	2020
												f	E
	Amounts owed by group VAT		undertakings									662,607 304	504,115 304
												662,911	504,419

Year Ended 31 Janua 2	Year Ended 31 Janua 2	021	021
CREDITORS: AMOUNTS		FALLING DUE WITHIN ONE		YEAR
					2021	2020
Amounts owed to group undertakings Accruals and deferred income					145,567 2,428	74,582 2,427
					147,995	77,009
MOVEMENT IN FUNDS
				Net	Transfers
				movement	between	At
			At 1/2/20	in funds	funds	31/1/21
			f		E	8
Unrestricted funds
General fund			1,082,281	16,287	(42,782)	1,055,786
Restricted funds
National Audit Programmes			1,014			1,014
National Liragutide & Scheme	Exenatide		29,489			29,489
Degludec Nationwide Canagliflozin audit Libre audit	Audit		19,465 63,032 69,236	(11,236) 53,728		19,465 51,796 122,964
Testosterone audit			79,664	(31,236)		48,428
Semaglutide audit Empagliflozin audit ABCD Research fund			131,665	99,106 3,764 (42,520)	42,520	230,771 3,764
Haemodialysis project COVID Diabetes National		Audit	2,061	(2,323) 10,000	262	10,000
			395,626	79,283	42,782	517,691
TOTAL FUNDS			1,477,907	95,570		1,573,477
Net movement in funds,		included	in the above are as follows:
			Incoming	Resources	Gains and	Movement
			resources 8	expended 8	losses f	in funds E
Unrestricted funds
General fund			8,862	(9,842)	17,267	16,287
Restricted funds
Canagliflozin audit Libre audit			5,000 72,477	(16,236) (18,749)		(11,236) 53,728
Testosterone audit			5,000	(36,236)		(31,236)
Semaglutide audit Empagliflozin audit ABCD Research fund			115,342 20,000	(16,236) (16,236) (42,520)		99,106 3,764 (42,520)
Haemodialysis project COVID Diabetes National		Audit	10,000	(2,323)		(2,323) 10,000
			227,819	(148,536)		79,283
TOTAL FUNDS			236,681	(158,378)	17,267	95,570

Comparatives for mo	veme	nt in fund	s
					Net	Transfers
					movement	between		At
				At 1/2/19	in funds	funds		31/1/20
					E	F		E
Unrestricted funds
General fund				991,461	132,113	(41,293)		1,082,281
Restricted funds
National Audit Programmes				1,238	(224)			1,014
NHS Priorities Scheme				11,725	(48,081)	36,356
National Liragutide &	Exenatide
Scheme				37,566	(8,077)			29,489
Revise Research Project				5,186	(9,446)	4,260
Degludec Nationwide Audit Nationwide Audit Therapies		Audit fund		27, 542	(8,077) (195)		195	19,465
Canagliflozin audit Libre audit				61,429 44,470	1,603 24,766			63,032 69,236
Testosterone audit				67,742	11,922			79,664
Semaglutide audit				81,242	50,423			131,665
Empagliflozin audit Haemodialysis project					(482) 2,061		482	2,061
				338,140	16,193	41,293		395,626
TOTAL FUNDS			1,329,601		148,306			1,477,907
Comparative net movement		in funds,	included	in the above	are as follows:
				Incoming	Resources	Gains and		Movement
				resources	expended	losses		in funds
				E	8	5		E
Unrestricted funds
General fund				127,205	(15,578)	20,486		132,113
Restricted funds
National Audit Programmes					(224)			(224)
NHS Priorities Scheme					(48,081)			(48,081)
National Liragutide 8	Exenatide
Scheme					(8,077)			(8,077)
Revise Research Project					(9,446)			(9,446)
Degludec Nationwide	Audit				(8,077)			(8,077)
Nationwide Audit Therapies		Audit fund			(195)			(195)
Canagliflozin audit Libre audit				20,000 80,642	(18,397) (55,876)			1,603 24,766
Testosterone audit				45,000	(33,078)			11,922
Semaglutide audit				68,500	(18,077)			50,423
Empagliflozin audit Haemodialysis project				10,000 2,500	(10,482) (439)			(482) 2,061
				226,642	(210,449)			16,193
TOTAL FUNDS				353,847	(226,027)	20,486		148,306

A current year 12 mon	ths	a	nd prior year	12 months combi	ned position is	as follows:
					Net	Transfers
					movement	between	At
				At 1/2/19	in funds	funds	31/1/21
				f	f	5	6
Unrestricted funds
General fund				991,461	148,400	(84,075)	1,055,786
Restricted funds
National Audit Programmes				1,238	(224)		1,014
NHS Priorities Scheme				11,725	(48,081)	36,356
National Liragutide &	Exenatide
Scheme				37,566	(8,077)		29,489
Revise Research Project Degludec Nationwide Audit Nationwide Audit Therapies Canagliflozin audit Libre audit			Audit fund	5,186 27, 542 61,429 44,470	(9,446) (8,077) (195) (9,633) 78,494	4,260 195	19,465 51,796 122,964
Testosterone audit				67,742	(19,314)		48,428
Semaglutide audit Empagliflozin audit				81,242	149,529 3,282	482	230,771 3,764
ABCD Research fund					(42,520)	42,520
Haemodialysis project COVID Diabetes National		Audit			(262) 10,000	262	10,000
				338,140	95,476	84,075	517,691
TOTAL FUNDS				1,329,601	243,876		1,573,477

Detailed Statement of Financial	Detailed Statement of Financial	Detailed Statement of Financial	Activities
for the Year Ended 31 Janua			2021
				2021	2020
				6	F
INCOME AND ENDOWMENTS
Donations and legacies
Donations				4,521	122,389
Investment Income
Dividend income				4,329	4,791
Deposit account interest				12	25
				4,341	4,816
Charitable activities
Semaglutide audit				115,341	68,500
Libre audit				72,478	80,642
Testosterone audit				5,000	45,000
Canagliflozin audit				5,000	20,000
Empagliflozin audit				20,000	10,000
Haemodialysis project					2,500
COVID diabetes national		audit		10,000
				227,819	226,642
Total incoming resources				236,681	353,847
EXPENDITURE
Charitable activities
National Audit Programme					224
NHS Priorities Scheme					48,081
Canagliflozin Audit Scheme				16,236	18,397
Revise Research project Libre audit				18,749	9,446 55,876
Liraglutide & Exenatide	Audit				8,077
Testosterone audit				36,236	33,078
Semaglutide audit				16,236	18,077
Degludec audit Nationwide new therapies		audit		2,323	8,077 195
Empagliflozin audit				16,236	10,482
ABCD Research fund				42,520
Haemodialysis project					439
				148,536	210,449
Support costs
Management Accountancy fees Insurance				3,953 1,959	3,643 1,599
Trustee costs				58	8,716
Professional fees				1,150
Carried forward				7,120	13,958

Detailed Statement	of	Financial	Activities
for the Year Ended	31	Janua	2021
				2021	2020
				F	E
Management
Brought forward				7,120	13,958
Investment manager		fees		2,650	1,548
Bank charges				72	72
				9,842	15,578
Total resources expended				158,378	226,027
Net Income before	gains and		losses	78,303	127,820
Realised recognised		gains and losses
Realised gains/(losses)		on fixed	asset
investments				17,267	20,486
Net Income				95,570	148,306